Mind the Gap: The Realities of Novel Irritable Bowel Syndrome Drug Access in Asian Clinical Practice.

This article explores the challenges of accessing novel drugs for irritable bowel syndrome (IBS) in Asian clinical practice. It emphasizes the importance of developing and implementing new IBS drugs that consider the unique characteristics of each region. However, selecting appropriate drugs is difficult due to the complex nature of IBS. The article also discusses the limited availability of novel IBS drugs in Asian countries, which can be attributed to high prices and lack of specific indications. It provides information on the availability of recommended drugs for IBS-C and IBS-D in various Asian countries, including Eluxadoline, Rifaximin, Alosetron, and Ramosetron. The text highlights the need for collaboration between patient advocacy groups, policymakers, and pharmaceutical companies to address the healthcare needs of Asian populations with IBS. [Extracted from the article]